 Nes Ziona, Israel, Feb. 12, 2021 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. NASDAQ: ENLV, a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of 20.00 per ordinary share, less underwriting discounts and commissions. 